Homepage
Author:
Deerfield Group
Posted Date:
April 9, 2026
Deerfield Group Names Bill Veltre as Chief Media Officer
Deerfield Group
April 9, 2026
AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension
Deerfield Group
April 9, 2026
Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
Deerfield Group
April 2, 2026
Petrichor Names Paul Sekhri as Operating Partner
Deerfield Group
April 1, 2026
Averna Therapeutics Announces Strategic Leadership Expansion
Deerfield Group
March 26, 2026
GentiBio Announces First Participant Dosed in POLARIS Phase 1 Clinical Trial of GNTI-122 in Recently Diagnosed Type 1 Diabetes
Deerfield Group
March 18, 2026
Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting
Deerfield Group
March 17, 2026
Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia
Deerfield Group
March 5, 2026
K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO
Deerfield Group
February 8, 2026
Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
Deerfield Group
February 4, 2026
1
2
Next
